The fund has started a stock position in biotech firm Ibio Inc.. The company's mission is " developing therapeutics and vaccines for the betterment of human and animal health" and has a patented plant based testing system named Fastpharming. The fund believes Ibio is positioned well during this time of epidemic and has experience with its previous work on SARS. They have connections all around the world and a first class facility in Bryan, Texas.
Technically, the stock price is leveling at $1.00 with a lot of room to run. There will likely be a short term move to 2.00 with any positive news and to $300 or above on positive revenue news. We believe this will happen in the next 6 months.
**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.
No comments:
Post a Comment